Loading…
Serum metabolomics can predict the outcome of first systematic transrectal prostate biopsy in patients with PSA <10 ng/ml
To assess the predictive value of metabolomic analysis for the presence of prostate cancer (PCa) at first systematic biopsy. Ninety serum samples from patients with suspicion for PCa were included. Targeted and nontargeted metabolomic analysis was performed. Six metabolites were combined into a pred...
Saved in:
| Published in: | Future oncology (London, England) England), 2017-08, Vol.13 (20), p.1793-1800 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c371t-aea1b73f95dc37e098c8fdd2f62a4406b3f90d888955c75edb83f2cb3d32babd3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c371t-aea1b73f95dc37e098c8fdd2f62a4406b3f90d888955c75edb83f2cb3d32babd3 |
| container_end_page | 1800 |
| container_issue | 20 |
| container_start_page | 1793 |
| container_title | Future oncology (London, England) |
| container_volume | 13 |
| creator | Andras, Iulia Crisan, Nicolae Vesa, Stefan Rahota, Razvan Romanciuc, Florina Lazar, Andrei Socaciu, Carmen Matei, Deliu-Victor de Cobelli, Ottavio Bocsan, Ioan-Stelian Coman, Radu-Tudor |
| description | To assess the predictive value of metabolomic analysis for the presence of prostate cancer (PCa) at first systematic biopsy.
Ninety serum samples from patients with suspicion for PCa were included. Targeted and nontargeted metabolomic analysis was performed.
Six metabolites were combined into a predictive score. A cutoff value of 0.528 for the metabolomic score showed a good accuracy for the prediction of PCa at biopsy (Area under the curve (AUC): 0.779; p < 0.001). These results were validated in a subgroup of patients, showing similar accuracy (p = 0.1). For patients with prostate specific antigen (PSA) less than 10 ng/ml, the score showed a Se 80.95%, Sp 64.52% for the detection of PCa at biopsy.
Metabolomic analysis can predict the outcome of the first systematic biopsy. |
| doi_str_mv | 10.2217/fon-2017-0078 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2275875184</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2275875184</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-aea1b73f95dc37e098c8fdd2f62a4406b3f90d888955c75edb83f2cb3d32babd3</originalsourceid><addsrcrecordid>eNp1kEtLJDEURoM4-BqXbiXgujRJpSopcCPijELDDDizDnnc2Gk6VW2SQvrfm6bVnaubx8l3cw9CF5RcM0bFjZ_GhhEqGkKEPEAnVHDeyJbQw7rmYmj6fuDH6DTnFSFctB05QsdMCtFzRk_Q9hnSHHGEos20nmKwGVs94k0CF2zBZQl4moudYq0e-5BywXmbC0RdgsUl6TEnsEWv65spF10AmzBt8haHGlMhGEvGb6Es8d_nO3xLCR5fbuL6J_rh9TrD-Uc9Q_9_Pfy7f2wWf34_3d8tGtsKWhoNmhrR-qFz9QDIIK30zjHfM8056U29Ik5KOXSdFR04I1vPrGldy4w2rj1DV_vc-r3XGXJRq2lOY22pGBOdFB2VvFLNnrJ1iDqQV5sUok5bRYnaiVZVtNqJVjvRlb_8SJ1NBPdFf5qtwLAH_FzmBNlWDxbUfhd3csMI34S_Ax43juI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2275875184</pqid></control><display><type>article</type><title>Serum metabolomics can predict the outcome of first systematic transrectal prostate biopsy in patients with PSA <10 ng/ml</title><source>PubMed Central</source><creator>Andras, Iulia ; Crisan, Nicolae ; Vesa, Stefan ; Rahota, Razvan ; Romanciuc, Florina ; Lazar, Andrei ; Socaciu, Carmen ; Matei, Deliu-Victor ; de Cobelli, Ottavio ; Bocsan, Ioan-Stelian ; Coman, Radu-Tudor</creator><creatorcontrib>Andras, Iulia ; Crisan, Nicolae ; Vesa, Stefan ; Rahota, Razvan ; Romanciuc, Florina ; Lazar, Andrei ; Socaciu, Carmen ; Matei, Deliu-Victor ; de Cobelli, Ottavio ; Bocsan, Ioan-Stelian ; Coman, Radu-Tudor</creatorcontrib><description>To assess the predictive value of metabolomic analysis for the presence of prostate cancer (PCa) at first systematic biopsy.
Ninety serum samples from patients with suspicion for PCa were included. Targeted and nontargeted metabolomic analysis was performed.
Six metabolites were combined into a predictive score. A cutoff value of 0.528 for the metabolomic score showed a good accuracy for the prediction of PCa at biopsy (Area under the curve (AUC): 0.779; p < 0.001). These results were validated in a subgroup of patients, showing similar accuracy (p = 0.1). For patients with prostate specific antigen (PSA) less than 10 ng/ml, the score showed a Se 80.95%, Sp 64.52% for the detection of PCa at biopsy.
Metabolomic analysis can predict the outcome of the first systematic biopsy.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2017-0078</identifier><identifier>PMID: 28776421</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Accuracy ; Aged ; Amino acids ; Antigens ; Biomarkers ; Biopsy ; Diagnosis, Differential ; Discriminant analysis ; Humans ; Male ; Medical screening ; Metabolites ; Metabolome ; metabolomics ; Metabolomics - methods ; Middle Aged ; Mortality ; NMR ; Nuclear magnetic resonance ; Patients ; prediction score ; Prognosis ; Prostate cancer ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - diagnosis ; ROC Curve ; Software ; Systematic review ; Ultrasonic imaging ; Variables</subject><ispartof>Future oncology (London, England), 2017-08, Vol.13 (20), p.1793-1800</ispartof><rights>2017 Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd Aug 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-aea1b73f95dc37e098c8fdd2f62a4406b3f90d888955c75edb83f2cb3d32babd3</citedby><cites>FETCH-LOGICAL-c371t-aea1b73f95dc37e098c8fdd2f62a4406b3f90d888955c75edb83f2cb3d32babd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28776421$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Andras, Iulia</creatorcontrib><creatorcontrib>Crisan, Nicolae</creatorcontrib><creatorcontrib>Vesa, Stefan</creatorcontrib><creatorcontrib>Rahota, Razvan</creatorcontrib><creatorcontrib>Romanciuc, Florina</creatorcontrib><creatorcontrib>Lazar, Andrei</creatorcontrib><creatorcontrib>Socaciu, Carmen</creatorcontrib><creatorcontrib>Matei, Deliu-Victor</creatorcontrib><creatorcontrib>de Cobelli, Ottavio</creatorcontrib><creatorcontrib>Bocsan, Ioan-Stelian</creatorcontrib><creatorcontrib>Coman, Radu-Tudor</creatorcontrib><title>Serum metabolomics can predict the outcome of first systematic transrectal prostate biopsy in patients with PSA <10 ng/ml</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>To assess the predictive value of metabolomic analysis for the presence of prostate cancer (PCa) at first systematic biopsy.
Ninety serum samples from patients with suspicion for PCa were included. Targeted and nontargeted metabolomic analysis was performed.
Six metabolites were combined into a predictive score. A cutoff value of 0.528 for the metabolomic score showed a good accuracy for the prediction of PCa at biopsy (Area under the curve (AUC): 0.779; p < 0.001). These results were validated in a subgroup of patients, showing similar accuracy (p = 0.1). For patients with prostate specific antigen (PSA) less than 10 ng/ml, the score showed a Se 80.95%, Sp 64.52% for the detection of PCa at biopsy.
Metabolomic analysis can predict the outcome of the first systematic biopsy.</description><subject>Accuracy</subject><subject>Aged</subject><subject>Amino acids</subject><subject>Antigens</subject><subject>Biomarkers</subject><subject>Biopsy</subject><subject>Diagnosis, Differential</subject><subject>Discriminant analysis</subject><subject>Humans</subject><subject>Male</subject><subject>Medical screening</subject><subject>Metabolites</subject><subject>Metabolome</subject><subject>metabolomics</subject><subject>Metabolomics - methods</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Patients</subject><subject>prediction score</subject><subject>Prognosis</subject><subject>Prostate cancer</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>ROC Curve</subject><subject>Software</subject><subject>Systematic review</subject><subject>Ultrasonic imaging</subject><subject>Variables</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp1kEtLJDEURoM4-BqXbiXgujRJpSopcCPijELDDDizDnnc2Gk6VW2SQvrfm6bVnaubx8l3cw9CF5RcM0bFjZ_GhhEqGkKEPEAnVHDeyJbQw7rmYmj6fuDH6DTnFSFctB05QsdMCtFzRk_Q9hnSHHGEos20nmKwGVs94k0CF2zBZQl4moudYq0e-5BywXmbC0RdgsUl6TEnsEWv65spF10AmzBt8haHGlMhGEvGb6Es8d_nO3xLCR5fbuL6J_rh9TrD-Uc9Q_9_Pfy7f2wWf34_3d8tGtsKWhoNmhrR-qFz9QDIIK30zjHfM8056U29Ik5KOXSdFR04I1vPrGldy4w2rj1DV_vc-r3XGXJRq2lOY22pGBOdFB2VvFLNnrJ1iDqQV5sUok5bRYnaiVZVtNqJVjvRlb_8SJ1NBPdFf5qtwLAH_FzmBNlWDxbUfhd3csMI34S_Ax43juI</recordid><startdate>20170801</startdate><enddate>20170801</enddate><creator>Andras, Iulia</creator><creator>Crisan, Nicolae</creator><creator>Vesa, Stefan</creator><creator>Rahota, Razvan</creator><creator>Romanciuc, Florina</creator><creator>Lazar, Andrei</creator><creator>Socaciu, Carmen</creator><creator>Matei, Deliu-Victor</creator><creator>de Cobelli, Ottavio</creator><creator>Bocsan, Ioan-Stelian</creator><creator>Coman, Radu-Tudor</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20170801</creationdate><title>Serum metabolomics can predict the outcome of first systematic transrectal prostate biopsy in patients with PSA <10 ng/ml</title><author>Andras, Iulia ; Crisan, Nicolae ; Vesa, Stefan ; Rahota, Razvan ; Romanciuc, Florina ; Lazar, Andrei ; Socaciu, Carmen ; Matei, Deliu-Victor ; de Cobelli, Ottavio ; Bocsan, Ioan-Stelian ; Coman, Radu-Tudor</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-aea1b73f95dc37e098c8fdd2f62a4406b3f90d888955c75edb83f2cb3d32babd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Accuracy</topic><topic>Aged</topic><topic>Amino acids</topic><topic>Antigens</topic><topic>Biomarkers</topic><topic>Biopsy</topic><topic>Diagnosis, Differential</topic><topic>Discriminant analysis</topic><topic>Humans</topic><topic>Male</topic><topic>Medical screening</topic><topic>Metabolites</topic><topic>Metabolome</topic><topic>metabolomics</topic><topic>Metabolomics - methods</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Patients</topic><topic>prediction score</topic><topic>Prognosis</topic><topic>Prostate cancer</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>ROC Curve</topic><topic>Software</topic><topic>Systematic review</topic><topic>Ultrasonic imaging</topic><topic>Variables</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Andras, Iulia</creatorcontrib><creatorcontrib>Crisan, Nicolae</creatorcontrib><creatorcontrib>Vesa, Stefan</creatorcontrib><creatorcontrib>Rahota, Razvan</creatorcontrib><creatorcontrib>Romanciuc, Florina</creatorcontrib><creatorcontrib>Lazar, Andrei</creatorcontrib><creatorcontrib>Socaciu, Carmen</creatorcontrib><creatorcontrib>Matei, Deliu-Victor</creatorcontrib><creatorcontrib>de Cobelli, Ottavio</creatorcontrib><creatorcontrib>Bocsan, Ioan-Stelian</creatorcontrib><creatorcontrib>Coman, Radu-Tudor</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Andras, Iulia</au><au>Crisan, Nicolae</au><au>Vesa, Stefan</au><au>Rahota, Razvan</au><au>Romanciuc, Florina</au><au>Lazar, Andrei</au><au>Socaciu, Carmen</au><au>Matei, Deliu-Victor</au><au>de Cobelli, Ottavio</au><au>Bocsan, Ioan-Stelian</au><au>Coman, Radu-Tudor</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum metabolomics can predict the outcome of first systematic transrectal prostate biopsy in patients with PSA <10 ng/ml</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2017-08-01</date><risdate>2017</risdate><volume>13</volume><issue>20</issue><spage>1793</spage><epage>1800</epage><pages>1793-1800</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>To assess the predictive value of metabolomic analysis for the presence of prostate cancer (PCa) at first systematic biopsy.
Ninety serum samples from patients with suspicion for PCa were included. Targeted and nontargeted metabolomic analysis was performed.
Six metabolites were combined into a predictive score. A cutoff value of 0.528 for the metabolomic score showed a good accuracy for the prediction of PCa at biopsy (Area under the curve (AUC): 0.779; p < 0.001). These results were validated in a subgroup of patients, showing similar accuracy (p = 0.1). For patients with prostate specific antigen (PSA) less than 10 ng/ml, the score showed a Se 80.95%, Sp 64.52% for the detection of PCa at biopsy.
Metabolomic analysis can predict the outcome of the first systematic biopsy.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>28776421</pmid><doi>10.2217/fon-2017-0078</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2017-08, Vol.13 (20), p.1793-1800 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_proquest_journals_2275875184 |
| source | PubMed Central |
| subjects | Accuracy Aged Amino acids Antigens Biomarkers Biopsy Diagnosis, Differential Discriminant analysis Humans Male Medical screening Metabolites Metabolome metabolomics Metabolomics - methods Middle Aged Mortality NMR Nuclear magnetic resonance Patients prediction score Prognosis Prostate cancer Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - diagnosis ROC Curve Software Systematic review Ultrasonic imaging Variables |
| title | Serum metabolomics can predict the outcome of first systematic transrectal prostate biopsy in patients with PSA <10 ng/ml |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T13%3A55%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20metabolomics%20can%20predict%20the%20outcome%20of%20first%20systematic%20transrectal%20prostate%20biopsy%20in%20patients%20with%20PSA%20%3C10%20ng/ml&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Andras,%20Iulia&rft.date=2017-08-01&rft.volume=13&rft.issue=20&rft.spage=1793&rft.epage=1800&rft.pages=1793-1800&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2017-0078&rft_dat=%3Cproquest_cross%3E2275875184%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c371t-aea1b73f95dc37e098c8fdd2f62a4406b3f90d888955c75edb83f2cb3d32babd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2275875184&rft_id=info:pmid/28776421&rfr_iscdi=true |